EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Dave & Buster's (NASDAQ: PLAY ) posted first quarter earnings Tuesday evening, and the stock is flying off of the report. Shares had been in a nasty downtrend into the April low, but have now recovered much of the previous losses, withJosh Arnold has been covering financial markets for a decade, utilizing a combination of technical and fundamental analysis to identify potential winners early on in their growth cycles. Josh's focus is mainly on growth stocks. His goal is efficient and profitable use of capit ...

Warner Bros. Discovery TodayWBDWarner Bros. Discovery$10.01 +0.48 (+5.04%) 52-Week Range$6.64▼$12.70Price Target$12.17Add to WatchlistRecent volatility in Warner Bros. Discovery NASDAQ: WBD stock is tied directly to a landmark strategic pivot. Since its formation in April 2022, the entertainment sector giant has traded at what many analysts have called a conglomerate discount, where the combined company's stock is valued for less than the sum of its individual parts. In a decisive move to address this, the ...

TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX studyMore than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 3b AP ...

In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 MedianFLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced initial results as of June 10, 2025, from the CLOVER-2 Phase 1 clinical trial evaluating iopofosine I 131 in relapsed/refractory pediatric high-grade glioma ...

IBM (IBM) has announced a bold step forward in the quantum computing race with Starling, the world’s first large-scale fault-tolerant quantum computer. Slated for release in 2029, Starling will be housed in IBM’s newly established quantum data center in upstate New York. According to IBM, the system will perform 20,000 times more operations than current quantum machines, as quoted on Yahoo Finance.Why Fault Tolerance MattersThe breakthrough feature of Starling is its ability to operate without errors. This ...

First quarter consolidated net revenues totaled $51.7 million Financial condition remains strong with $86 million in liquidity and no debt FORT WAYNE, Ind., June 11, 2025 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced its financial results for the first quarter of the fiscal year ending January 31, 2026 (“Fiscal 2026”). First Quarter Comments Jackie Ardrey, Chief Executive Officer commented, “Our first quarter results were disappointing as top line and profitability tre ...

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Thursday, June 12, 2025. Conference details are as follows: H.C. Wainwright “HCW@Home with vTv ...

ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a distinguished career and significant contributions to the Company. Baldor brings mor ...

CEO Jackie Ardrey will be departing the Company Ian Bickley will assume the role of Executive Chairman Martin Layding is joining the Company as Chief Financial Officer New Board Strategy and Transformation Committee Established FORT WAYNE, Ind., June 11, 2025 (GLOBE NEWSWIRE) -- Vera Bradley (Nasdaq: VRA) (the “Company”) today announced that its Chief Executive Officer, Jacqueline Ardrey is leaving the Company. The Board of Directors has launched a national search for Ms. Ardrey’s replacement. She will rema ...